Mikrobiol. Z. 2022; 84(1):57-64.
doi: https://doi.org/10.15407/microbiolj84.01.057

The Role of Intestinal Microbiota and Its Recovery in COVID-19

S. Starovoitova1, O. Demchenko2, V. Bila2, M. Spivak3

1National University of Food Technologies
68 Volodymyrska Str., Kyiv, 01601, Ukraine

2Kyiv Perinatal Center
9 Predslavynska Str., Kyiv, 03150, Ukraine

3Zabolotny Institute of Microbiology and Virology, NAS of Ukraine
154 Acad. Zabolotny Str., Kyiv, 03143, Ukraine

Today, during the SARS-CoV-2 pandemic, when there are no clear therapeutic strategies for prevention and treatment, attention should be paid to alternative treatments, which may include the use of bacteriotherapeutic drugs based on probiotic microorganisms, i.e. representatives of the host normobiota. Experimental data show that changes in immune balance in patients with SARS-CoV-2 may be mediated by corresponding changes in the host intestinal microbiota. This statement is especially significant for the elderly, whose intestinal biota is less diverse. Especially the number of useful representative’s decreases, which leads to greater sensitivity of the older generation to SARS-CoV-2. The composition and function of the intestinal microbiota may be a potential biological mechanism responsible for the diversity of susceptibility of different groups of people to SARS-CoV-2. A bidirectional connection along the intestinelung axis due to soluble microbial metabolites transported by the bloodstream is shown. The intestinal microbiota produces many diffusing metabolites with immunomodulatory properties. Given the potential beneficial effects of bacteriotherapeutic drugs and functional foods enriched with probiotic microbiota during respiratory viral infection, their use as therapeutic agents during SARS-CoV-2 infection can be considered. Since the microbiota can be maintained using adequate, safe, and relatively inexpensive bacteriotherapeutic drugs (pro-, pre-, para-, post-, synbiotics, immunobiotics, functional foods enriched with probiotic microorganisms, etc.), their use should be considered as adjunctive therapy to limit SARS-CoV-2 progression in infected patients or as a prophylactic strategy for uninfected people at risk during the expansion of SARS-CoV-2.

Keywords: microbiome, probiotics, SARS-CoV-2, normobiota, probiotic microorganisms.

Full text (PDF, in English)

  1. Ceccarelli G, Borrazzo C, Pinacchio C, Santinelli L, Innocenti GP, Cavallari EN, et al. Oral bacteriotherapy in patients with COVID-19: a retrospective cohort study. Front Nutr. 2021; 7:1–8. https://doi.org/10.3389/fnut.2020.613928
  2. Conte L, Toraldo DM. Targeting the gut–lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection. Ther Adv Respir Dis. 2020; 14:1–5. https://doi.org/10.1177/1753466620937170
  3. d’Ettorre G, Ceccarelli G, Marazzato M, Campagna G, Pinacchio C, Alessandri F, et al. Challenges in the Management of SARS-CoV-2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19. Front Med. 2020; 7(389):1–7. https://doi.org/10.3389/fmed.2020.00389
  4. Gautier T, David-Le Gall S, Sweidan A, Tamanai-Shacoori Z, Jolivet-Gougeon A, Loréal O, Bousarghin L. Next-Generation Probiotics and Their Metabolites in COVID-19. Microorganisms. 2021; 9:1–13. https://doi.org/10.3390/microorganisms9050941
  5. Gohil K, Samson R, Dastager S, Dharne M. Probiotics in the prophylaxis of COVID-19: something is better than nothing. 3 Biotech. 2021; 11(1):1–10. https://doi.org/10.1007/s13205-020-02554-1
  6. Huang C, Wang Y, Li X, Lu Y, Zhu X, Li Y, et al. Inical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
  7. Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, et al. Management of corona virus disease-19 (COVID-19): the Zhejiang experience. J Zhejiang Univ. (medical science). 2020; 49(1):147–157.
  8. Starovoitova SO, Antonyuk MM. Vzayemozvyazok normobioty kyshechnyku ta osoblyvosti perebihu Covid-19. In: Aktualni pytannya diahnostyky COVID-19: zb. materialiv Vseukrayinskoyi naukovo-praktychnoyi konferentsiyi, m. Rivne; 2021, Feb 18–19; Rivne: Rivnensʹka medychna akademiya; 2021. p. 109–113. Ukrainian.
  9. Starovoitova SA, Karpov AV. Immunobiotiki i ikh vliyaniye na immunnuyu sistemu cheloveka v norme i pri patologii. Biotechnology. Theory and Practice. 2015; 4:10–20. Russian.
  10. Dhar D, Mohanty A. Gut microbiota and Covid-19 – possible link and implications. Virus Res. 2020; 285:198018. https://doi.org/10.1016/j.virusres.2020.198018
  11. Dumas A, Bernard L, Poquet Y, Lugo-Villarino G, Neyrolles O. The Role of the Lung Microbiota and the Gut-Lung Axis in Respiratory Infectious Diseases. Cell Microbiol. 2018; 20:e12966. https://doi.org/10.1111/cmi.12966
  12. Yeoh YK, Zuo T, Lui GC-Y, Zhang F, Liu Q, Li AYL, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021; 70(4):698–706. https://doi.org/10.1136/gutjnl-2020-323020
  13. Kurian SJ, Unnikrishnan MK, Miraj SS, Bagchi D, Banerjee M, Reddy BS, et al. Probiotics in prevention and treatment of COVID-19: current perspective and future prospects. Archives of Medical Research. 2021; 16:1–13. https://doi.org/10.1016/j.arcmed.2021.03.002
  14. Stavropoulou E, Bezirtzoglou E. Probiotics as a weapon in the fight against COVID-19. Frontiers in Nutrition. 2020; 7:1–4. https://doi.org/10.3389/fnut.2020.614986
  15. Mak JWY, Chan FKL, Ng SC. Probiotics and COVID-19: one size does not fit all. Lancet Gastroenterol Hepatol. 2020; 5(7):644–645. https://doi.org/10.1016/S2468-1253(20)30122-9
  16. Olaimat AN, Aolymat I, Al-Holy M, Ayyash M, Ghoush MA, Al-Nabulsi AA, et al. The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19. Science of Food. 2020; 4:1–7. https://doi.org/10.1038/s41538-020-00078-9
  17. Zafar N, Aslam MA, Ali A, Khatoon A, Nazir A, Tanveer Q, et al. Probiotics: Helpful for theprevention of COVID-19? Biomedical Research and Therapy. 2020; 7(11):4086–4099. https://doi.org/10.15419/bmrat.v7i11.646
  18. Dang AT, Marsland BJ. Microbes, Metabolites, and the Gut–Lung Axis. Mucosal Immunol. 2019; 12:843–850. https://doi.org/10.1038/s41385-019-0160-6
  19. Lobel L, Garrett WS. Take DAT, Flu! Immunity. 2017; 47(3):400–402. https://doi.org/10.1016/j.immuni.2017.09.002
  20. Hang S, Paik D, Yao L, Kim E, Trinath J, Lu J, et al. Bile Acid Metabolites Control TH17 and Treg Cell Differentiation. Nature. 2019; 576:143–148. https://doi.org/10.1038/s41586-019-1785-z
  21. Wang F, Pan B, Xu S, Xu Z, Zhang T, Zhang Q, et al. A meta-analysis reveals the effectiveness of probiotics and prebiotics against respiratory viral infection. Bioscience Reports. 2021; 41(3):BSR20203638. https://doi.org/10.1042/BSR20203638
  22. Graham BS, Johnson TR, Peebles RS. Immunemediated disease pathogenesis in respiratory syncytial virus infection. Immunopharmacology. 2000; 48:237–247. https://doi.org/10.1016/S0162-3109(00)00233-2
  23. Kullar R, Johnson S, McFarland LV, Goldstein EJC. Potential Roles for Probiotics in the Treatment of COVID-19 Patients and Prevention of Complications Associated with Increased Antibiotic Use. Antibiotics. 2021; 10(4):1–10. https://doi.org/10.3390/antibiotics10040408
  24. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020; 81:537–540. https://doi.org/10.1002/ddr.21656
  25. General Office of the National Health Commission Notice on the issuance of COVID-19 diagnosis and treatment plan. State Administration of Hospital Administration. 2020. http://www.nhc.gov.cn/yzygj/s7653p/202001/4294563ed35b43209b31739bd0785e67.shtml
  26. Khaled JMA. Probiotics, prebiotics, and COVID-19 infection: A review article. Saudi Journal of Biological Sciences. 2021; 28:865–869. https://doi.org/10.1016/j.sjbs.2020.11.025
  27. Jayawardena R, Sooriyaarachchi P, Chourdakis M, Jeewandara C, Ranasinghe P. Enhancing immunity in viral infections, with special emphasis on COVID-19: A review. Diabet Metabol Syndrome Clin Res Rev. 2020; 14(4):367–382. https://doi.org/10.1016/j.dsx.2020.04.015
  28. Mirzaei R, Attar A, Papizadeh S, Jeda AS, Hosseini-Fard SR, Jamasbi E, et al. The emerging role of probiotics as a mitigation strategy against coronavirus disease 2019 (COVID-19). Archives of Virology. 2021; 166(7):1819–1840. https://doi.org/10.1007/s00705-021-05036-8
  29. Rosa RB, Dantas WM, do Nascimento JCF, da Silva MV, de Oliveira RN, Pena LJ. In vitro and in vivo Models for Studying SARS-CoV-2, the Etiological Agent Responsible for COVID-19 Pandemic. Viruses. 2021; 13(379):1–29. https://doi.org/10.3390/v13030379
  30. Soloveva IV, Ilyicheva TN, Marchenko VYu, Pyankov OV, Tochilina AG, Belova IV, et al. Genome Features and in vitro Activity against Influenza A and SARS-CoV-2 Viruses of Six Probiotic Strains. BioMed Research International. 2021: 6662027. https://doi.org/10.1155/2021/6662027
  31. Zuo T, Wu X, Wen W, Lan P. Gut Microbiome Alterations in COVID-19. Genomics Proteomics Bioinformatics. 2021; 21:1–25. https://doi.org/10.1016/j.gpb.2021.09.004